Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
暂无分享,去创建一个
S. Loibl | N. Burchardi | I. Vergote | J. Sehouli | P. Wimberger | A. Belau | U. Wagner | C. Kurzeder | A. Bois | J. Pfisterer